

NOTE: Refer to the relevant section and question number from the Initial Visit form. Fax Checklist to Coordinating Center.

Clinic	Number: Site Number: ID. Number:	C	Na	me Cod	le:		
<u>eye c</u>	haracteristics						
(To be	confirmed by the Ophthalmologist after review of angiogram)	<u>RIGH</u> Yes	<u>Γ ΕΥΕ</u> Νο		<u>LEFT</u> Yes	<u>EYE</u> No	
V.1.	10 or more large drusen (${>}125\mu)$ within 3000 μ of foveal center	()	(STO	P)	()	(STO	P)
V.2.	Geographic atrophy $>$ 1 MPS disc area within 3000 microns of the foveal center	(STOP)	()	(STOP)	()
V.2.	Geographic atrophy within 500 microns of the foveal center	(STOP)	()	(STOP)	()
V.3.	Signs of diabetic retinopathy worse than 10 red dots or macula edema	(STOP)	()	(STOP)	()
V.4.	Retinal changes related to high myopia	(STOP)	()	(STOP)	()
V.5.	Glaucoma likely to affect central vision within 5 years	(STOP)	()	(STOP)	()
V.7a.	Lens removal or implantation less than three months ago	(STOP)	()	(STOP)	()
V.7b.	Capsulotomy within the past three days	(STOP)	()	(STOP)	()
V.8.	Any lens opacity that will preclude good photography	(STOP)	()	(STOP)	()
V.9.	Evidence of CNV now or in the past	(STOP)	()	(STOP)	()
V.10.	Serous Pigment Epithelial Detachment	(STOP)	()	(STOP)	()
V.11.	Previous laser photocoagulation treatment to the retina	(STOP)	()	(STOP)	()
V.12.	Any other ocular disease	(****)	()	(****)	()
	Date approved by Reading Center:		•	-			

PATIENT ELIGIBILITY	Ye	s	No	Yes	s No		
II.3.o. & 4.o. Visual acuity total number correct 43 (20/40) or better	()	(STOP)	() (STOP)		
VI.2. & 5. Color stereo photographs and fluorescein angiogram taken							
Photo date:	()	(STOP)	() (STOP)		
Was all required visual function testing completed within 28 days prior to randomization?	()	(STOP)	() (STOP)		



Clinic	Number: Site Number: ID. Number:	·	- C	Name Code:
<u>PATIE</u>	NT ELIGIBILITY (continued)		Yes	No
I.3.	Age 50 years or older		()	(STOP)
I.78.	Exclusionary history of macular toxic drugs		(STOP)	()
l.17a.	Condition that makes 5-year survival unlikely		(STOP)	()
l.17b.	Limits to activity making follow-up unlikely		(STOP)	()
l.17c.	Signed informed consent form		()	(STOP)
I.15.	Participating in any other study		(****)	()
	Approved by Coordinating Center:			
V.6.	Currently taking macular toxic glaucoma drugs		(STOP)	()
<u>Clini</u>	<u>C Responsibilities</u>	Y	(es	No
1.	Complete Patient Information questionnaire		()	(STOP)
2.	Complete Initial Visit Form		()	(STOP)
3.	Complete Quality of Life Assessment		()	(STOP)
4.	Any reservations about enrolling this patient		(STOP)	()
5.	Check here if a Pre-randomization Review was submitte Reading Center	d to the	()	
6.	Check here if the patient is also enrolled in AREDS:		()	
		6A. AREDS Re	gistratio	on Number:
		6B. AREDS Na	ıme Cod	e:
7.	Print name and certification number of ophthalmologist	L		
	reviewing this checklist:///			